KR100545431B1 - 축합된 이종방향족 글루코키나제 활성화제 - Google Patents

축합된 이종방향족 글루코키나제 활성화제 Download PDF

Info

Publication number
KR100545431B1
KR100545431B1 KR1020037007517A KR20037007517A KR100545431B1 KR 100545431 B1 KR100545431 B1 KR 100545431B1 KR 1020037007517 A KR1020037007517 A KR 1020037007517A KR 20037007517 A KR20037007517 A KR 20037007517A KR 100545431 B1 KR100545431 B1 KR 100545431B1
Authority
KR
South Korea
Prior art keywords
cyclopentyl
phenyl
propionamide
methanesulfonyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037007517A
Other languages
English (en)
Korean (ko)
Other versions
KR20030068555A (ko
Inventor
코벳웬디리
그림시조셉사무엘
하이네스낸시-엘렌
케스터로버트프랜시스
마하네이페이지에린
사라부라마칸트
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20030068555A publication Critical patent/KR20030068555A/ko
Application granted granted Critical
Publication of KR100545431B1 publication Critical patent/KR100545431B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
KR1020037007517A 2000-12-06 2001-11-28 축합된 이종방향족 글루코키나제 활성화제 Expired - Fee Related KR100545431B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25163700P 2000-12-06 2000-12-06
US60/251,637 2000-12-06
PCT/EP2001/013870 WO2002046173A1 (en) 2000-12-06 2001-11-28 Fused heteroaromatic glucokinase activators

Publications (2)

Publication Number Publication Date
KR20030068555A KR20030068555A (ko) 2003-08-21
KR100545431B1 true KR100545431B1 (ko) 2006-01-24

Family

ID=22952803

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037007517A Expired - Fee Related KR100545431B1 (ko) 2000-12-06 2001-11-28 축합된 이종방향족 글루코키나제 활성화제

Country Status (21)

Country Link
US (3) US6545155B2 (enExample)
EP (1) EP1341774B1 (enExample)
JP (1) JP4109111B2 (enExample)
KR (1) KR100545431B1 (enExample)
CN (1) CN1226294C (enExample)
AR (1) AR031627A1 (enExample)
AT (1) ATE316965T1 (enExample)
AU (2) AU2002221902B2 (enExample)
BR (1) BR0115999A (enExample)
CA (1) CA2429642C (enExample)
DE (1) DE60117059T2 (enExample)
DK (1) DK1341774T3 (enExample)
ES (1) ES2256340T3 (enExample)
GT (1) GT200100243A (enExample)
MX (1) MXPA03005119A (enExample)
PA (1) PA8534301A1 (enExample)
PE (1) PE20020753A1 (enExample)
PT (1) PT1341774E (enExample)
UY (1) UY27055A1 (enExample)
WO (1) WO2002046173A1 (enExample)
ZA (1) ZA200303748B (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
RU2340605C2 (ru) 2002-06-27 2008-12-10 Ново Нордиск А/С Арилкарбонильные производные в качестве терапевтических средств
EP1531815B1 (en) * 2002-06-27 2014-09-24 Novo Nordisk A/S Glucokinase activators
US6775812B2 (en) * 2002-07-17 2004-08-10 Hewlett-Packard Development Company, L.P. Layout design process and system for providing bypass capacitance and compliant density in an integrated circuit
PL375149A1 (en) 2002-10-03 2005-11-28 F.Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
RU2005113713A (ru) * 2002-10-03 2006-01-20 Новартис АГ (CH) Замещенные (тиазол-2-ил)амиды или сульфонамиды в качестве активаторов глюкокиназы, которые могут применяться при лечении диабета типа 2
GB0226931D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
JP4621198B2 (ja) * 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
ATE390922T1 (de) * 2003-06-20 2008-04-15 Hoffmann La Roche 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
WO2005066145A1 (en) 2004-01-06 2005-07-21 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
US20080312207A1 (en) * 2004-02-18 2008-12-18 Craig Johnstone Compounds
ES2322709T3 (es) * 2004-02-18 2009-06-25 Astrazeneca Ab Derivados de benzamida y su uso como agentes activadores de la glucocinasa.
WO2005095417A1 (en) * 2004-04-02 2005-10-13 Novartis Ag Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
ATE524479T1 (de) * 2004-04-02 2011-09-15 Novartis Ag Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
NZ550567A (en) * 2004-04-21 2010-07-30 Prosidion Ltd Tri(cyclo) substituted amide compounds
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
AU2005271016A1 (en) 2004-08-12 2006-02-16 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
AU2005293343B2 (en) 2004-10-16 2009-03-19 Astrazeneca Ab Process for making phenoxy benzamide compounds
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
KR20070083939A (ko) * 2004-11-02 2007-08-24 반유 세이야꾸 가부시끼가이샤 아릴옥시 치환된 벤즈이미다졸 유도체
DE102005012872A1 (de) * 2005-03-19 2006-09-28 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Pyrrolidino-benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20110059941A1 (en) * 2005-05-24 2011-03-10 Peter William Rodney Caulkett 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
BRPI0622261A2 (pt) 2005-07-09 2011-08-09 Astrazeneca Ab composto, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
EP1910350A1 (en) * 2005-07-09 2008-04-16 AstraZeneca AB 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
WO2007007910A1 (ja) * 2005-07-13 2007-01-18 Banyu Pharmaceutical Co., Ltd. ヘテロ環置換ベンズイミダゾール誘導体
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
RU2008112198A (ru) 2005-09-29 2009-10-10 Санофи-Авентис (Fr) Производные фенил-1,2,4-оксадиазолона, способы их получения и их применение в качестве фармацевтических средств
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
US20090005391A1 (en) * 2005-11-03 2009-01-01 Matthew Colin Thor Fyfe Tricyclo Substituted Amides
EP1948614A2 (en) * 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
AT503354B1 (de) * 2006-02-22 2008-07-15 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von 3,4-disubstituierten phenylessigsäuren, sowie neue zwischenverbindungen
EP2001875A2 (en) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
ATE522518T1 (de) 2006-05-31 2011-09-15 Takeda San Diego Inc Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
BRPI0715531A2 (pt) 2006-07-24 2014-06-24 Hoffmann La Roche Composto, composição farmacêutica, método para o tratamento de uma enfermidade e/ou distúrbio metabólico, processo para a preparação de compostos e uso do composto
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
CL2007003061A1 (es) * 2006-10-26 2008-08-01 Astrazeneca Ab Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
RU2009121756A (ru) * 2006-12-21 2011-01-27 Астразенека Аб (Se) Новое кристаллическое соединение, полезное в качестве активатора глюкокиназы (glk)
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
WO2008111473A1 (ja) * 2007-03-07 2008-09-18 Kyorin Pharmaceutical Co., Ltd. グルコキナーゼ活性化物質
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
CL2009000004A1 (es) * 2008-01-15 2010-02-19 Lilly Co Eli Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
KR20100113518A (ko) 2008-01-18 2010-10-21 아스텔라스세이야쿠 가부시키가이샤 페닐아세트아미드 유도체
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
SI2275414T1 (sl) 2008-04-28 2015-10-30 Kyorin Pharmaceutical Co., Ltd., Ciklopentilakrilamidni derivat
KR20110052676A (ko) 2008-08-04 2011-05-18 아스트라제네카 아베 피라졸로[3,4]피리미딘-4-일 유도체 및 당뇨병 및 비만을 치료하기 위한 이의 용도
JP5937353B2 (ja) * 2008-08-19 2016-06-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ 冷感−メントール受容体拮抗剤
EA201100311A1 (ru) 2008-09-11 2011-10-31 Пфайзер Инк. Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
EP2604604A1 (en) 2009-03-11 2013-06-19 Pfizer Inc Benzofuranyl derivatives used as glucokinase inhibitors
AR076221A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
US8222416B2 (en) * 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
ES2893699T3 (es) 2010-03-31 2022-02-09 Scripps Research Inst Reprogramación de células
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP3366698A1 (en) 2011-03-01 2018-08-29 Synergy Pharmaceuticals Inc. Guanylate cyclase c agonists
ES2489297B1 (es) 2013-01-22 2015-06-10 Consejo Superior De Investigaciones Científicas (Csic) Benzotiazoles sustituidos y sus aplicaciones terapeuticas para el tratamiento de enfermedades humanas
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
MX389591B (es) 2014-08-29 2025-03-20 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
JP6684516B2 (ja) 2015-05-15 2020-04-22 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ Ｒｏｒガンマ調節物質としての置換型テトラヒドロキノリン化合物
US20180134667A1 (en) 2016-10-14 2018-05-17 TES Pharma S.r.I. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
MX2022015525A (es) 2020-06-08 2023-03-23 Vtv Therapeutics Llc Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxi ciclohexil)ureido]tiazol-5-ilsulfanil}acetico y usos de los mismos.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3840550A (en) * 1971-05-24 1974-10-08 Ciba Geigy Corp Certain 6-isothiocyanobenzothiazoles
CN1151140C (zh) * 1999-03-29 2004-05-26 霍夫曼-拉罗奇有限公司 葡糖激酶活化剂
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators

Also Published As

Publication number Publication date
DE60117059T2 (de) 2006-10-26
CN1476438A (zh) 2004-02-18
DE60117059D1 (de) 2006-04-13
US6448399B1 (en) 2002-09-10
PE20020753A1 (es) 2002-08-27
CA2429642C (en) 2007-11-20
CA2429642A1 (en) 2002-06-13
DK1341774T3 (da) 2006-06-12
CN1226294C (zh) 2005-11-09
US20020107396A1 (en) 2002-08-08
KR20030068555A (ko) 2003-08-21
JP2004517087A (ja) 2004-06-10
AU2002221902B2 (en) 2006-11-23
PA8534301A1 (es) 2002-08-26
US20020103241A1 (en) 2002-08-01
AR031627A1 (es) 2003-09-24
EP1341774B1 (en) 2006-02-01
WO2002046173A1 (en) 2002-06-13
ZA200303748B (en) 2004-08-16
EP1341774A1 (en) 2003-09-10
PT1341774E (pt) 2006-05-31
AU2190202A (en) 2002-06-18
MXPA03005119A (es) 2004-10-15
ATE316965T1 (de) 2006-02-15
UY27055A1 (es) 2002-07-31
JP4109111B2 (ja) 2008-07-02
BR0115999A (pt) 2003-09-30
US20020103199A1 (en) 2002-08-01
ES2256340T3 (es) 2006-07-16
US6545155B2 (en) 2003-04-08
GT200100243A (es) 2002-06-04
US6441184B1 (en) 2002-08-27

Similar Documents

Publication Publication Date Title
KR100545431B1 (ko) 축합된 이종방향족 글루코키나제 활성화제
US6433188B1 (en) Fused heteroaromatic glucokinase activators
KR100502032B1 (ko) 트랜스 올레핀 글루코키나제 활성화제
AU2002221902A1 (en) Fused heteroaromatic glucokinase activators
EP1311504B1 (en) Tetrazolyl-phenyl acetamide glucokinase activators
EP1349856B1 (en) Isoindolin-1-one glucokinase activators
EP1282611B1 (en) Substituted phenylacetamides and their use as glucokinase activators
EP1501815B1 (en) Substituted phenylacetamides and their use as glucokinase activators
AU2001283998A1 (en) Tetrazolyl-phenyl acetamide glucokinase activators

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20091230

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110117

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110117

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000